Patents by Inventor James L. Cole

James L. Cole has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6748351
    Abstract: An apparatus for electronic warfare signal simulation which is used in an external test system to simultaneously test a plurality of “victim” communication systems for vulnerability to jamming. The test system includes a remote radiator of a signal free of jamming effects, and a remote radiator of one or more radio frequency control signals which represent one or more predetermined jamming threats in the low and mid bands.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: June 8, 2004
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mark W. Hynes, Robert L. Weeks, James L. Cole, Robert E. Reiner, Timothy T. Taylor
  • Patent number: 6369208
    Abstract: A method is provided for making synthetic capped RNAs. These compounds serve as substrates for the virally encoded endonuclease associated with influenza virus. We are able to assay for this unique and specific viral activity of cleavage of a capped RNA in vitro. Therefore, screening of inhibitors of this activity is possible. In addition, short non-extendible (due to their length or because of the modification of the 3′-end of the oligo, i.e. 3′-dA) RNAs are potent inhibitors of the cleavage of capped RNAs by influenza endonuclease. Finally, these compounds may be used to investigate viral and cellular mechanisms of transcription/translation or mRNA maturation.
    Type: Grant
    Filed: March 30, 1998
    Date of Patent: April 9, 2002
    Assignee: Merck & Co., Inc.
    Inventors: James L. Cole, Lawrence C. Kuo, David B. Olsen, Fritz Benseler
  • Patent number: 6111095
    Abstract: A method is provided for making synthetic capped RNAs. These compounds serve as substrates for the virally encoded endonuclease associated with influenza virus. We are able to assay for this unique and specific viral activity of cleavage of a capped RNA in vitro. Therefore, screening of inhibitors of this activity is possible. In addition, short non-extendible (due to their length or because of the modification of the 3'-end of the oligo, i.e. 3'-dA) RNAs are potent inhibitors of the cleavage of capped RNAs by influenza endonuclease. Finally, these compounds may be used to investigate viral and cellular mechanisms of transcription/translation or mRNA maturation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 29, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Fritz Benseler, James L. Cole, David B. Olsen, Lawrence C. Kuo
  • Patent number: 6100028
    Abstract: The present invention provides rapid accurate sensitive assays specific for the detection of at least one a single stranded oligonucleotide produced by the action of an enzyme on a substrate. The assays are useful to detect the presence in a sample of an enzyme which acts on an oligonucleotide substrate to generate a single stranded oligonucleotide product and to detect inhibitors of such an enzyme.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: August 8, 2000
    Assignee: Merck & Co., Inc.
    Inventors: James L. Cole, Lawrence C. Kuo, David B. Olsen
  • Patent number: 5886626
    Abstract: A system is tested for jamming resistance by supplying a simulated jamming ignal. The simulated jamming signal is produced by calculating a propagation path loss in the terrain between the system under test and a location where the jammer would be, predicting a jamming level in accordance with the propagation path loss, and generating a simulated jamming signal. The simulated jamming signal is supplied to the antenna port of the system under test. The testing does not require the use of either a real jammer or a pilot signal generator at the location where the jammer would be.
    Type: Grant
    Filed: October 1, 1997
    Date of Patent: March 23, 1999
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mark W. Hynes, James L. Cole, Barry C. Miller, Scott A. Morris, Robert E. Reiner
  • Patent number: 5861501
    Abstract: A method is provided for making synthetic capped RNAs. These compounds serve as substrates for the virally encoded endonuclease associated with influenza virus. We are able to assay for this unique and specific viral activity of cleavage of a capped RNA in vitro. Therefore, screening of inhibitors of this activity is possible. In addition, short non-extendible (due to their length or because of the modification of the 3'-end of the oligo, i.e. 3'-dA) RNAs are potent inhibitors of the cleavage of capped RNAs by influenza endonuclease. Finally, these compounds may be used to investigate viral and cellular mechanisms of transcription/translation or mRNA maturation.
    Type: Grant
    Filed: February 4, 1997
    Date of Patent: January 19, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Fritz Benseler, James L. Cole, David B. Olsen, Lawrence C. Kuo
  • Patent number: 5660989
    Abstract: An assay for the influenza virus endonuclease has been developed which involves DNA polymerase-catalyzed extension of the viral endonuclease cleavage product using labeled nucleotides and a DNA template containing a 3' region complementary to the product joined to a 5' region consisting of repeated residues. The DNA polymerase coupled assay does not involve gel electrophoretic separation and is amenable to high volume screening of potential inhibitors. Another key feature of the assay is that it is sensitive enough to detect 200 attomoles of product.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 26, 1997
    Assignee: Merck & Co., Inc.
    Inventors: James L. Cole, Lawrence C. Kuo, David B. Olsen
  • Patent number: 5583509
    Abstract: A communications electronic warfare trainer that includes apparatus and a thod by which a training umpire can control the localized jamming of a victim communications system. A control signal containing an address and duration of jamming is generated and transmitted using the same frequency as the victim communications system. The control signal is processed by a Receiver Unit collocated with the victim communications system to determine if the control signal address matches the address of the victim communications system. If an address match is found, a jamming signal is produced for the specified duration causing disruption of the normal operation of the victim communications system.
    Type: Grant
    Filed: July 20, 1995
    Date of Patent: December 10, 1996
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mark W. Hynes, James L. Cole, Garrett W. Conover, Michael J. O'Connor